key: cord-0617335-vnz9wox5 authors: Wang, Yuhong; Michael, Sam; Huang, Ruili; Zhao, Jinghua; Recabo, Katlin; Bougie, Danielle; Shu, Qiang; Shinn, Paul; Sun, Hongmao title: Retro Drug Design: From Target Properties to Molecular Structures date: 2021-05-11 journal: nan DOI: nan sha: b170bcbae742ba8eadc8371712925de80d0243d2 doc_id: 617335 cord_uid: vnz9wox5 To generate drug molecules of desired properties with computational methods is the holy grail in pharmaceutical research. Here we describe an AI strategy, retro drug design, or RDD, to generate novel small molecule drugs from scratch to meet predefined requirements, including but not limited to biological activity against a drug target, and optimal range of physicochemical and ADMET properties. Traditional predictive models were first trained over experimental data for the target properties, using an atom typing based molecular descriptor system, ATP. Monte Carlo sampling algorithm was then utilized to find the solutions in the ATP space defined by the target properties, and the deep learning model of Seq2Seq was employed to decode molecular structures from the solutions. To test feasibility of the algorithm, we challenged RDD to generate novel drugs that can activate {mu} opioid receptor (MOR) and penetrate blood brain barrier (BBB). Starting from vectors of random numbers, RDD generated 180,000 chemical structures, of which 78% were chemically valid. About 42,000 (31%) of the valid structures fell into the property space defined by MOR activity and BBB permeability. Out of the 42,000 structures, only 267 chemicals were commercially available, indicating a high extent of novelty of the AI-generated compounds. We purchased and assayed 96 compounds, and 25 of which were found to be MOR agonists. These compounds also have excellent BBB scores. The results presented in this paper illustrate that RDD has potential to revolutionize the current drug discovery process and create novel structures with multiple desired properties, including biological functions and ADMET properties. Availability of an AI-enabled fast track in drug discovery is essential to cope with emergent public health threat, such as pandemic of COVID-19. The primary goal of modern drug discovery is to identify molecules of therapeutic benefits. A successful drug molecule usually shares two features: 1. It modulates the biological function of its therapeutic target(s) selectively with sufficient binding affinity; 2. It has a balanced ADMET (absorption, distribution, metabolism, excretion, and toxicity) profile, such that it reaches its target(s) unchanged and with sufficient quantity. Traditionally, a drug discovery project starts with screening a compound library against a proposed protein target, followed by an optimization process to fix existing issues associated with original hit compounds, such as potency, selectivity, PK, and etc. This traditional drug discovery process requires tremendous input of resources and time. Computational generation of high-quality drug candidates with desired properties, a long-sought goal of pharmaceutical research, will not only reduce the unprecedented cost of bringing a drug to market dramatically (Paul, Mytelka et al. 2010 , Hughes, Rees et al. 2011 , DiMasi, Grabowski et al. 2016 , it will also dramatically speed up the whole process. Accelerated drug development is of paramount importance for public health threats of pandemics such as COVID-19 (Administration 2020, Grobler, Anderson et al. 2020) The deep learning (DL) technology (LeCun, Bengio et al. 2015 , Schmidhuber 2015 ) brings hope to a new era of drug discovery and development and have the potential of substantially improving or even revolutionizing the current drug discovery paradigm. DL utilizes multiple layers of neurons to model high-level abstractions, complex and non-linear relation in data, and has outperformed humans in many fields including image processing, text and voice recognition, protein structure prediction and GO game; yet this potential in drug discovery remains to be fulfilled. Various machine learning and deep learning algorithms have been proposed over the past decade for generation of novel molecules with therapeutic benefits. Kadurin et al (Kadurin, Nikolenko et al. 2017) , Blascheke et al (Blaschke, Olivecrona et al. 2018) , and Lim et al (Lim, Ryu et al. 2018 ) used autoencoder, variational autoencoder and adversarial autoencoder to identify and generate new molecular fingerprints with predefined properties. Bjerrum and Threlfall (Esben jannik Bjerrum 2017), Cherti et al (Medhdi Cherti 2017) , and Segler et al (Segler, Kogej et al. 2018 ) utilized recurrent neural network, in particular, the long short-term memory (LSTM) model (Hochreiter and Schmidhuber 1997) to generate novel molecular structures with certain target properties. The autoencoder and RNN models are quite limited for generating novel molecules of preferred properties. These models are not designed to assess, or optimize, the properties of the generated molecules. Furthermore, quality of deep learning models is largely determined by data quality and quantity on which they are based, and unfortunately the sample size and data quality of available experimental drug discovery data are usually insufficient for deep learning methods. To address the limitations of autoencoder and RNN models, various reinforcement learning (RL) (RS Sutton 1998) and generative adversarial networks (GAN) (Ian Goodfellow 2014) have been proposed and implemented for sequence generation. These models typically consist of sequence generation model, RL, and GAN. The RL and GAN models are used to optimize and move the generated molecules towards the target properties. Olivecrona et al (Olivecrona, Blaschke et al. 2017 ) introduced a method to tune a sequencebased generative model for de novo molecular design. Sanchez-Lengeling et al (Benjamin Sanchez-Lengeling 2017) presented ORGANIC, a framework based on both GAN and RL, which is capable of producing a distribution over molecular space that matches with a certain set of desirable metrics. Popova et al (Popova, Isayev et al. 2018 ) devised and implemented a novel computational strategy for de novo design of molecules with desired properties. As a typical strategy, it includes a generative model that produces chemically valid SMILES string, predictive models that forecast the desired properties of the de novo-generated compounds, and a reinforcement learning module that tips the generated structures to have the desired properties. Putin et al (Putin, Asadulaev et al. 2018 ) reported a deep neural network, ATNC or Adversarial Threshold Neural Computer, for the de novo design of novel small-molecule organic structures with druglikeness properties. Zhou et al (Zhou, Kearnes et al. 2019) presented a framework, called Molecule Deep Q-Networks (MolDQN), for molecule optimization by combining domain knowledge of chemistry and state-of-the-art reinforcement learning techniques (double Q-learning and randomized value functions). One advantage of MolDQN is that it can produce structures of 100% chemical validity. Zhavoronkov (Zhavoronkov, Ivanenkov et al. 2019 ) developed a deep generative model, generative tensorial reinforcement learning (GENTRL), for de novo small-molecule design, and GENTRL produced several compounds, which were active in biochemical assays and cell-based assays. Ikebata et al (Ikebata, Hongo et al. 2017) used Bayesian model to identify promising hypothetical molecules with a predefined set of desired properties. Most of the efforts in de novo molecular design are based upon deep neural networks, in particular, RNN, GAN, and RL. While these DL methods demonstrated the good potential in drug discovery, they are not ready for prime time in typical drug discovery projects. First, deep learning models require a very large number of good quality samples. Unfortunately, available experimental data for drug discovery are limited in both quality and quantity. Second, current methods are not efficient for sampling molecular structural space. To generate new valid chemical structures, a method can only perform local, small, and slow perturbations on representations like SMILES string (Daylight) or graph; such sampling method is apparently not sufficient considering the vast possible chemical and structural space. This may partially explain why GENTRL took 21 days to produce several active compounds. Sampling regardless chemical structure validity will lead to very small percentage of produced structures to be valid. For example, only 7% of the generated structures by ORGANIC is valid. Third, RL algorithms tend to have difficulties in achieving a good balance of exploration and exploitation, making long term credit assignment, and being unstable likely due to moving target. Fourth, with RL, it is theoretically possible to optimize multiple target properties, but in practice, current implementations use either one target property or weighted sum of multiple target properties. Here we propose a new strategy called Retro Drug Design (RDD). Unlike the current forward approaches as described above, RDD starts from multiple desired target properties, works backwards, and then generates the "qualified" compound structures. RDD is based upon following rationales and considerations. First, although the amount of available discovery data of small molecules for drug targets and ADMET properties is insufficient for deep learning models, it is sufficient for traditional, or shallow, machine learning models. Second, over the past decades, we developed a generic fingerprint called ATP of 269 descriptors (Sun 2015) . The same ATP descriptors have achieved outstanding performance in traditional machine learning prediction models of all the physicochemical and ADMET properties, accessible to us. ATP is originally designed to have good correspondence with SMILES; in other words, one SMILES produces one ATP, and one ATP corresponds to as few SMILES as possible. Third, many millions of valid compound structures are readily available, and they provide a good coverage of valid chemical space of small molecules. To test our algorithm, we generated 180,000 ligands for µ opioid receptor (MOR) systems (Al-Hasani and Bruchas 2011), selected and tested 96 in cAMP assay in hMOR-CHO cells. Opioids are the most widely used and effective analgesics for the treatment of pain and related disorders, most commonly used opioids for pain management act on MOR, and the cAMP assay is mature and reliable. An optimized atom-type-based molecular descriptor system, or ATP, consisting of 221 atom types and 48 correction factors was employed to represent small molecules. The details of the molecular descriptors have been elaborated elsewhere (Sun 2015) . Atom types are assigned according to the properties of an atom and its chemical environment. An atom type casting tree was designed to assign atom types, based on whether the atom is aromatic, whether the atom is in a ring, whether the atom is next to different functional groups, etc. This original tree, largely based on a medicinal chemist's intuition, was subject to a recursive optimization cycles in terms of where to further split the tree, where to stop splitting, and where to combine the branches, in order to make the best prediction of logP values in the Starlist dataset containing about 11,000 structurally diverse compounds. (Sun 2015) An atom in a molecule is like a piece of puzzle chip in a puzzle, which has its unique edge. When a set of puzzle chips are provided, the puzzle can be solved unambiguously, on the basis of unique shape of each piece. The optimized tree output 221 atom types, featuring 88 different carbon types, 7 hydrogen types, 58 nitrogen types, 31 oxygen types, 8 halide types, 23 sulfur types, and number of whole molecule features, such as the molecular globularity, molecular rigidity, lipophilicity, and etc. (Sun 2015) In total, a series of 269 numerical values comprise the final set of the atom type molecular descriptors. Using ATP representation, we could design molecules of predefined properties by sampling in the ATP space of 269 dimensions. The workflow of RDD is illustrated in Figure 1 . RDD starts from a list of target properties and their preferred ranges, such as logP between 2 and 5, and the number of properties is only limited by available computing resources. The properties can be physicochemical properties, such as molecular size, solubility, and biological properties, such as hERG (Wikipedia) activity. In this study, all properties are computed from the same molecular representation system, ATP, through an evaluator, which could be a simple mathematical function, a traditional machine learning model, or a deep learning neural network model. The property range is defined by lower and upper boundaries of L0-Ln and U0-Un ( Figure 1 ). With the input list of target properties and their desired ranges, RDD uses a number of evaluators of E0-En ( Figure 1 ) and a Monte Carlo (MC) sampling algorithm to find solutions in the ATP space that have the desired ranges according to the corresponding evaluators. In order to sample in the more likely valid region of the ATP space, we calculated the mean (ATP_Mean) and the standard deviation (ATP_Std) from the ATP for 906,727 unique molecular structures in NCATS's compound collection. The MC algorithm consists of the following steps: 1. Start from a randomly initialized ATP, according to Equation 1 [ Where is a Gaussian random number generator with a mean of 0.0 and standard deviation of 1.0. Apply the evaluators and compute the output score ! . Then calculate the initial cost according to Equation 2. Where n is the number of properties or evaluators, wi is the weighting factor for the ith evaluator, Li and Ui are the lower and upper boundaries of the ith property. 2. Randomly pick 8 elements (optional) from previous , and randomly perturb each by adding 0.5*( -0.5) * _ [i] to propose a new atp. is a uniform random number generator between 0.0 and 1.0. 3. Recalculate the cost of the current . If the current cost is < 0.01 (optional), stop the sampling process and output the solution. If the current cost is smaller than the previous one, accept the perturbation; otherwise reject the perturbation. Go back to step 2. 4. If no solution is found after 50 steps, go back to step 1. 5. If no solution is found after 40,000 steps, stop and terminate. With the solution of atp in the ATP space from the Monte Carlo algorithm, next, RDD uses a deep learning model, called ATP2SMI, to map atp to molecular structures as represented by SMILES. ATP2SMI is adapted from the widely used seq2seq model (Google). A typical seq2seq model consists of an encoder and a decoder; the encoder transforms the sequence input to a vector of latent variables, which is then transformed to the output sequence by the decoder. In ATP2SMI, we removed the encoder, used ATP as the vector of latent variables, and then used a decoder to transform ATP to output sequence-SMILES ( Figure 2 ). vector. We ignored chirality in a molecular structure, mainly for simplification purpose, and plan to include chirality in the future studies. In the ATP2SMI, an atp is fed to a fully connected layer, FC, and the output is fed to decoder, a recurrent neural network of GRU cells. The number of units in the FC is the same as that in the GRU cell, and we tried four different numbers of units, 1024, 1280, 1536 and 2048. Sparse categorical cross entropy is used as the loss or cost function. Backpropagation is used for training the network (David E. Rumelhart 1986) . Optimization of the loss function is carried out by mini-batch of a size 128 and the ADAM optimizer (Diederik P. Kingma 2017) , which is implemented as tf.train.AdamOptimizer in the Tensorflow library (Tensorflow) . For the ADAM optimizer, a learning rate of 0.001 produced a satisfactory result. The model training process was monitored by two metrics: cost function and accuracy on both the training and validation datasets. The model with the best accuracy on the validation set is saved and applied to the test dataset to collect chemistry specific benchmarks. In this study, we compute three chemistry specific metrics. The first is the percentage of the generated structures that are chemically valid. A structure is considered valid if it is successfully parsed by ChemAxon's molecular parser (Chemaxon) . The second is the percentage of the valid structures that are identical to the ground truth. The third is the percentage of the structures that have a Tanimoto score > 0.95. In order to recognize ligands for MOR, a SVM model (Noble 2006) was constructed using the primary screening results. Among the 1707 preprocessed samples, 256 were assigned active and 1451 inactive. Apparently, this dataset was highly skewed. To address this data imbalance problem, we adopted the bootstrapping and Jackknifing method (Sun, Huang et al. 2017) . Briefly, the 1707 samples were randomly split into training dataset (80%) and test dataset (20%). The negative samples in the training dataset were further randomly split into 5 subsets, which were then combined with the positive samples to produce 5 sub training datasets. Five SVM models were trained using the to implement the ATP2SMI model. We We trained 4 ATP2SMI models using GRU cells of 1024, 1280, 1536 and 2048 units, and the accuracies of the optimized models on the test dataset are given in When ATP descriptor system was designed, one of the major motivations was to produce a molecular descriptor system that is universal, in other words, the same system can be applied to generate QSAR models for all properties. (Sun 2004) Our following efforts have proved that ATP can provide excellent QSAR models for all the datasets available to us, and most of the QSAR models achieved accuracy comparable to experimental determinations. (Sun 2005 , Sun, Veith et al. 2011 , Sun 2015 , Sun, Huang et al. 2017 , Sun, Nguyen et al. 2017 , Sun, Shah et al. 2019 , Sun, Wang et al. 2020 ) To achieve a universal molecular descriptor system, the descriptors should well represent the compound and extract its chemical meanings as accurately and adequately as possible. Atom typing meets these requirements. As long as each atom type carries enough information of its surrounding atoms and bonds, ATP descriptors and the corresponding SMILES is interconvertible. Therefore, choosing ATP is critical for the success of RDD. Opioids are the most widely used and effective analgesics for the treatment of pain and related disorders, and most commonly used opioids for pain management act on MOR. We chose MOR and the cAMP assay in hMOR-CHO cells to test our algorithm because the cAMP assay is available to us in-house and it is mature and reliable. Furthermore, opioid addiction is a huge challenge to worldwide public health, and this effort to generate potential ligands from RDD for MOR is part of the champaign of the HEAL program (NIH). MOR is a G-protein-coupled receptor (GPCR) and the target of most opioids, such as morphine. The crystal structures of MOR revealed a vast ligand binding pocket, which could accommodate small molecule agonists and peptide agonists, such as peptide MANGO ( Figure 4 ). This can explain the high hit rate of the primary assay. In this study, we aimed at generating MOR agonists with BBB permeability. Since small-size molecules with a polar surface area less than 60 Å 2 have a better opportunity to penetrate the BBB by passive diffusion, RDD will be induced to output MOR agonists of small or medium size. In order to test the RDD algorithm, we used three target properties. The first property was the Due to the limited the resources, we can only afford the purchasable chemicals. As a result, we (Table 2) . These 96 compounds were not high ranking ones among the 107,505 structures that were predicted to be MOR active. The highest ranking commercially available hit ranked 2,986 in the 139,720 RDD generated structures ( Figure 5 ). The striking feature observed in this study was the high percentage of the novel structures generated by RDD -only 267 out of nearly 140,000 RDD hits were commercially available. RL and GAN usually start from existing molecules and introduce different level of perturbation to generate new structures, so the new structures are generally close analogues of their templates. RDD started from random numbers, so the algorithm will not be restricted by existing seeds in terms of chemical space. In this sense, RDD is the authentic tool to explore the sub-space relevant to the targets and predefined properties unbiasedly. The advantage of RDD algorithm is obvious, i.e., it avoids searching the whole galaxy, which is inefficient assuming it is possible, for the target, instead, it explored only the small chemical space related to the targets. Another truth revealed by this study is the collection of commercially available compounds is tiny, and the vast chemical space is insufficiently investigated. Different from searching for a star in a vast galaxy, the strategy that the traditional drug discovery takes, RDD locates the star by exploring its neighboring subspace only. In this study, we have demonstrated that the RDD platform is capable of generating highly novel structures from scratch to meet predefined requirements, including MOR activity and BBB permeability. Nearly 180,000 chemical structures were generated from random numbers, among which 78% were chemically valid. About one third of the valid structures fell into the property space defined by MOR activity and BBB permeability. Out of the 42,000 qualified structures, only 267 chemicals were commercially available, indicating a high extent of novelty of the AI-generated compounds. We purchased and assayed 96 compounds, and 25 of which were found to be MOR agonists. These compounds were structurally diverse and had excellent BBB scores. The results presented in this paper illustrate that RDD has potential to greatly improve efficiency of drug discovery process, by creating novel structures with desired biological and ADMET properties. Availability of highly efficient and productive drug discovery platform is essential to handle emergent public health threat, such as pandemic of COVID-19. CSC1=CC=C(Cl)C(=C1)C(=O) CC1=CC=C(OCCC(=O)NC2=CC=CC(=C2)C#N) CC1CCN(CC1) CC1=CC=C(OCC(=O)N2CCN(CC2)C3=CC=CC=C3) CC1=C(C=CC=C1)N2CCN(CC2)C(=O)C3=CC=C(Cl) CN(CC1=CC=C(Br)C=C1)C2CCN(C) CSC1=CC=CC=C1C(=O)N2CCN(CC2)C3=CC=CC(Cl) CN(CC1=CC=CC=C1)C(=O) COC1CCCN(C1)C2=CC=C(NC(=O)C3=CC(F)=CC=C3) FC1=CC=C(CN2CCN(CC2)C3=CC=CC(Cl)=C3) FC1=CC=C(C=C1)N2CCN(CC2)C(=O) CC1=CC=CC=C1N2CCN(CC3=CC=CC=C3F) BrC1=CC=C(NC(=O)CN2CCC3=CC=CC=C3C2) CC(C)C(=O)N1CCCN(CC2=CC=CC=C2F) ClC1=C(C=CC=C1)N2CCN(CC(=O)NC3=CC=CC=C3) CN1CCC(CC1)OC2=CC=C(NC(=O)C3=CC=CC=C3F) C(N1CCCC(C1)C2=CC=CC=C2) ClC1=CC=C(C=C1)C2=NC(N3CCCC3) FC1=CC=CC(NCC(=O)N2CCC3=CC=CC=C3C2) CCC(=O)N(C)C1CCCN(C1) COC1=CC=C(CN2CCN(CC2)C3=CC=CC=C3F) CSC1=CC=CC=C1C(=O) ClC1=CC=C(SCC(=O)NC2CCCC3=CC=CC=C23) CC(NC(=O)CC1=CC=CC=C1Cl) ClC1=CC=C(C=C1)C(=O)N2CCN(CC2)C3=CC(Cl) CCCOC1=CC=C(CN2CCCC2C3=CC=C(F)C=C3) COC1=CC(=CC=C1)C(=O)NCCC2=CC=C(C=C2) FC1=CC=C(CC(=O)NCC2(CCCC2)C3=CC=CC=C3) CSC1=CC=C(CC(=O)N2CC(=O)NC3=CC=CC=C23) CCOC1=CC=C(CN2CCCC2C3=CC=C(F)C=C3) CC(=O)C1=CC=CC=C1NCC(=O) FC1=CC=CC=C1N2CCN(CC2)C(=O) CSC1=CC=CC=C1NC(=O) COC1=CC=C(C=C1)C(=O)N2CCN(CC2)C3=CC(Cl) FC1=CC=C(NC(=S)N2CCC3=CC=CC=C23) FC1=CC=CC(NC(=O)CCN2CCC(C2)C3=CC=CC=C3) COC1=CC=CC=C1NC2=NC(=CS2)C3=CC=C(C) O(C1=CC=CC=C1)C2=CC=C(C=C2) COC1=CC=CC(=C1)C(=O) CN1CCCN(CC1)C(=O)C2=CC=C(Cl) CC1=CC2=C(O)C=C(CSC3=CC=CC=C3) CN(CC(=O)NC1CCCC2=CC=CC=C12)CC3=CC(Cl) COC1=CC=CC=C1CCNC(=O) CC1=CC=CC=C1OCC(=O) CC1=CC=C(C=C1)N2COC3=CC=C(Br) CSC1=CC=C(CN(C)CC(=O)N2CCC3=CC=CC=C23) CC(C)N1CCC(CC1)NC(=O)CC2=CC=C(Cl) ClC1=CC=C(CCNC(=O)C2(CC2)C3=CC=CC=C3) CSC1=CC=CC=C1C(=O) ClC1=CC=C(C=C1)N2CCN(CC2)C(=O) FC1=CC=C(CCNC(=O)C2(CC2)C3=CC=CC=C3) CSC1=CC=C(CN(C)C(=O)C2=CC=C3C=CC=CC3=C2) OC1=C(C=NC2=CC(Cl)=CC=C12)C(=O) ClC1=CC=CC(CN2N=C(C=CC2=O)C3=CC=CC=C3) ClC1=CC=C(C=C1)N2CCN(CC3=CC=CC=C3) CSC1=CC=CC(NC(=O)C2=CN(C)C3=CC=CC=C23) Coronavirus Treatment Accelleration Program Molecular mechanisms of opioid receptor-dependent signaling and behavior Optimizing distributions over molecular space. An Objective-Reinforced Generative Adversarial Network for Inverse-design Chemistry (ORGANIC) Application of Generative Autoencoder in De Novo Molecular Design Training v-Support Vector Classifier: Theory and Algorithm Software solutions and services for chemistry & biology Learning representations by backpropagating errors SMILES Adam: A Method for Stochastic Optimization Innovation in the pharmaceutical industry: New estimates of R&D costs Molecular Generation with Recurrent Neural Networks (RNNs) Accelerated Preclinical Paths to Support Rapid Development of COVID-19 Therapeutics Long short-term memory The next level in chemical space navigation: going far beyond enumerable compound libraries Principles of early drug discovery Generative Adversarial Nets Bayesian molecular design with a chemical language model JOELib druGAN: An Advanced Generative Adversarial Autoencoder Model for de Novo Generation of New Molecules with Desired Molecular Properties in Silico Deep learning Molecular generative model based on conditional variational autoencoder for de novo molecular design Ultra-large library docking for discovering new chemotypes A Bayesian approach to in silico blood-brain barrier penetration modeling Helping to End Addiction Long-Term What is a support vector machine? Molecular de-novo design through deep reinforcement learning How to improve R&D productivity: the pharmaceutical industry's grand challenge Deep reinforcement learning for de novo drug design Adversarial Threshold Neural Computer for Molecular de Novo Design Reinforcement Learning: An Introduction Deep learning in neural networks: an overview Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks A universal molecular descriptor system for prediction of logP, logS, logBB, and absorption A naive bayes classifier for prediction of multidrug resistance reversal activity on the basis of atom typing A Practical Guide to Rational Drug Design. Cambridge Highly predictive and interpretable models for PAMPA permeability Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity Predictive models for cytochrome p450 isozymes based on quantitative high throughput screening data Predictive models for estimating cytotoxicity on the basis of chemical structures An end-to-end open source machine learning platform A grid algorithm for high throughput fitting of dose-response curve data hERG Deep learning enables rapid identification of potent DDR1 kinase inhibitors Optimization of Molecules via Deep Reinforcement Learning This research was supported in part by the Intramural/Extramural research program of the NCATS, NIH.